Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Headache|September 28, 2004
Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based studyRoger Cady, Vincent Martin, James Adelman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 3, 2008
Migraine frequency and health utilities: findings from a multisite surveyJeffrey S Brown, Peter J Neumann, George Papadopoulos, et al.
Headache|May 16, 2007
Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomesTimothy Smith, Harvey Blumenthal, Merle Diamond, et al.
Neurology|February 20, 2025
Real-world Evidence of Adding Atogepant to OnabotulinumtoxinA for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001)Andrew Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
Headache|June 15, 2005
Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraineKathleen A Foley, Roger Cady, Vincent Martin, et al.
Pain and Therapy|September 17, 2024
Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart ReviewAndrew M Blumenfeld, Laszlo Mechtler, Lisa Cook, et al.
JAMA|February 26, 2004
Topiramate for migraine prevention: a randomized controlled trialJan Lewis Brandes, Joel R Saper, Merle Diamond, et al.
The Journal of Headache and Pain|October 7, 2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) studyStephen Silberstein, Merle Diamond, Nada A Hindiyeh, et al.
Cephalalgia : an International Journal of Headache|January 9, 2023
Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trialBrad C Klein, Rosa Miceli, Lawrence Severt, et al.
NPJ Digital Medicine|May 13, 2026
Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine preventionShaheen E Lakhan, Mariya Petrova, Cassandra Snipes, et al.
Pageof 2